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ABBREVIATIONS 
ASE- American society of echocardiography 
BMI – Body mass index 
DM- Diabetes mellitus 
EDV- End diastolic volume 
EF- Ejection fraction 
ESV- End systolic volume 
FS-Fractional shortening 
HDL- High density lipoprotein 
IVSW- Inter ventricular septal wall 
LDL-Low density lipoprotein 
LV- Left ventricle 
LVEF- Left ventricular ejection fraction 
LVID (D)- Left ventricular internal diameter (diastolic) 
LVID(S)- Left ventricular internal diameter (systolic) 
LVPW- Left ventricular posterior wall 
T3- triiodothyronine  
T4- thyroxine 
TSH- Thyroid stimulating hormone 
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INTRODUCTION 
 
 
The thyroid gland maintains the level of metabolism in the tissues that is 
optimal for their normal function. The function of the thyroid is to generate the 
quantity of thyroid hormone necessary to meet the demands of the peripheral 
tissues. The principal hormones secreted by the thyroid are thyroxine (T4) and 
triiodothyronine (T3). T3 is also formed in the peripheral tissues by deiodination 
of T4. Both hormones are iodine-containing amino acids. Small amounts of reverse 
triiodothyronine (3, 3´, 5´-triiodothyronine, RT3) and other compounds are also 
found in thyroid venous blood. T3 is more active than T4, whereas RT3 is inactive. 
Anatomy 
The thyroid is one of the largest of the endocrine organs, weighing 
approximately 15 to 20 g. The normal thyroid is made up of two lobes joined by a 
thin band of tissue, the isthmus. The gland is composed of closely packed spherical 
units termed follicles, which are invested with a rich capillary network. The 
interior of the follicle is filled with the clear proteinaceous colloid that normally is 
the major constituent of the total thyroid mass (1). 
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Thyroid Hormone Synthesis 
The thyroid cell membranes facing the capillaries contain a symporter, or 
iodide pump, that transports Na+ and I- into the cells against the electrochemical 
gradient for I-. This Na+/I- symporter (NIS) is capable of producing intracellular I- 
concentrations that are 20-40 times as great as the concentration in plasma. 
In the thyroid gland, iodide is oxidized to iodine .In the process of hormone 
synthesis; the first product is monoiodotyrosine (MIT). MIT is next iodinated in 
the 5 position to form diiodotyrosine (DIT). Two DIT molecules then undergo an 
oxidative condensation to form T4 with the elimination of the alanine side chain 
from the molecule that forms the outer ring. Thyroid peroxidase is probably 
involved in coupling as well as iodination. T3 is probably formed by condensation 
of MIT with DIT. A small amount of RT3 is also formed, probably by condensation 
of  DIT with MIT and bound to the 3 position of tyrosine residues that are part of 
the thyroglobulin molecule in the colloid.(2) 
Secretion 
The human thyroid secretes about 80 ug (103 nmol) of T4, 4 ug (7 nmol) of T3, and 
2 ug (3.5 nmol) of RT3 per day .However, MIT and DIT are not secreted. The 
iodinated tyrosines are deiodinated by a microsomal iodotyrosine deiodinase.(2) 
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Transport & Metabolism 
 The plasma proteins that bind thyroid hormones are albumin; a prealbumin 
formerly called thyroxine-binding prealbumin (TBPA) and now called 
transthyretin; and a globulin with an electrophoretic mobility between those of 
α1- and α2-globulin, thyroxine-binding globulin (TBG). Of the three proteins, 
albumin has the largest capacity to bind T4—ie, it can bind the most T4 before 
becoming saturated—and TBG has the smallest capacity. 
Mechanism of Action 
 Thyroid hormones enter cells, and T3 binds to thyroid receptors (TR) in the 
nuclei. T4 can also bind, but not as avidly. The hormone-receptor complex then 
binds to DNA via zinc fingers and increases or in some cases decreases the 
expression of a variety of different genes that code for enzymes which regulate cell 
function. Thus, the nuclear receptors for thyroid hormones are members of the 
super family of hormone-sensitive nuclear transcription factors. There are two 
human TR genes: an α receptor gene on chromosome 17 and β receptor gene on 
chromosome 3. 
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Effects on the Cardiovascular System 
Thyroid hormone transcriptionally regulates many cardiac proteins the 
thyroid hormone exerts most of its direct effects on cardiac contractility by 
regulating calcium cycling through the SERCA-phospholamban system. 
 Thyroid hormone is an important regulator of cardiac function and 
cardiovascular hemodynamics. T(3) the physiologically active form of thyroid 
hormone, binds to nuclear receptor proteins and mediates the expression of several 
important cardiac genes, inducing transcription of the positively regulated genes 
including alpha-myosin heavy chain (MHC) and the sarcoplasmic 
reticulumcalcium ATPase. Negatively regulated genes include beta-MHC and 
phospholamban, which are down regulated in the presence of normal serum levels 
of thyroid hormone. T3 mediated effects on the systemic vasculature include 
relaxation of vascular smooth muscle resulting in decreased arterial resistance and 
diastolic blood pressure. In hyperthyroidism, cardiac contractility and cardiac 
output are enhanced and systemic vascular resistance is decreased, while 
in hypothyroidism, the opposite is true. Patients with subclinical 
hypothyroidism manifest many of the same cardiovascular changes, but to a lesser 
degree than that which occurs in overt hypothyroidism (3). 
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 An understanding of pathophysiology of cardiovascular changes of the 
thyroid enables prevention, early diagnosis and prompt intervention to control 
complications. Also the presence of cardiovascular complications may necessitate 
institution of therapy in patients of asymptomatic subclinical hypothyroidism. 
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AIM AND OBJECTIVE 
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AIM OF THE STUDY 
 
The aim of this study is to assess 
i. The cardiovascular functions in primary overt and subclinical 
hypothyroid patients.  
ii. To find a correlation between severity of disease and presence of 
significant echocardiographic changes. 
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                                REVIEW OF LITERATURE 
 
Thyroid diseases are among the commonest endocrine disorders worldwide. 
India, is no exception. There are various causes of primary hypothyroidism, but 
autoimmune disease (Hashimoto's thyroiditis) and thyroid failure following I 131 
or surgical treatment account for over 90% of cases in those parts of the world 
which are not significantly iodine-deficient. Iodine deficiency as a cause of 
hypothyroidism is more common in developing countries.  
The terminology  'subclinical hypothyroidism' was probably first used by 
Evered and colleagues to describe a group of individuals in whom 'conventional 
tests of thyroid function showed nothing abnormal ... but they were all found to 
have a raised serum TSH concentration' (Evered et al., 1973). Subclinical 
hypothyroidism is defined today by normal serum free T4 levels and serum TSH 
levels above the upper limit of the reference range. 
The clinical implications of subclinical hypothyroidism have provoked 
controversy. The progression to overt hypothyroidism is approximately 2–5% per 
year. Vanderpump MP et al in a follow up study states the rate of progression is 
proportional to baseline TSH concentration and is higher in individuals with 
antithyroid antibodies (4). Because of the high prevalence of subclinical 
hypothyroidism and its possible associations with cardiovascular disease, 
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dyslipidaemia and a host of other problems, as well as progression to overt 
hypothyroidism, it is important to screen the general population  and treat 
appropriate  patients.  
According to a survey by N. Kochupillai the countrywide prevalence of 
thyroid disorders is 42 millions. (5) Jayarama, K. S. et al the prevalence of 
hypothyroidism in India is 0.071 %.( 6). In a population-based study done in Cochin 
on 971 adult subjects, the prevalence of hypothyroidism was 3.9%. The prevalence 
of subclinical hypothyroidism was also high in this study, the value being 9.4%. In 
women, the prevalence was higher, at 11.4%, when compared with men, in whom 
the prevalence was 6.2%. (7) The worldwide prevalence of subclinical 
hypothyroidism ranges from 1% to 10%; the highest age and sex specific rates are 
in woman over 60 years, approaching to 20% (8, 9). 
 According to a study by Jangid DR et al thyroid surgery and decompensated 
iodine deficiency were the major known causes of hypothyroidism (19.5% and 
15.3% respectively), while in the majority of patients (45.14%) the aetiology was 
obscure.(10) 
 A review article by Shikha Bharaktiya states that the frequency of 
hypothyroidism, goiters, and thyroid nodules increases with age. Hypothyroidism 
is most prevalent in elderly populations, with 2% to as much as 20% of older age 
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groups having some form of hypothyroidism. The Framingham study found 
hypothyroidism (TSH >10 mIU/L) in 5.9% of women and 2.4% of men older than 
60 years (11). 
Causes of hypothyroidism 
Primary Hypothyroidism 
Acquired  
Hashimoto's thyroiditis  
Iodine deficiency (endemic goiter)  
Drugs blocking synthesis or release of T4 (e.g., lithium, ethionamide, sulfonamides, 
iodide)  
Goitrogens in foodstuffs or as endemic substances or pollutants  
Cytokines (interferon-α, interleukin-2)  
Thyroid infiltration (amyloidosis, hemochromatosis, sarcoidosis, Riedel's struma, 
cystinosis, scleroderma)  
Postablative due to 131I, surgery, or therapeutic irradiation for nonthyroidal 
malignancy  
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Congenital  
Iodide transport or utilization defect (NIS or pendrin mutations)  
Iodotyrosine dehalogenase deficiency  
Organification disorders (TPO* deficiency or dysfunction)  
Defects in thyroglobulin synthesis or processing  
Thyroid agenesis or dysplasia  
TSH receptor* defects  
Thyroidal Gs protein abnormalities (pseudohypoparathyroidism type 1a)  
Idiopathic TSH unresponsiveness  
Transient (Post-thyroiditis) Hypothyroidism  
Following subacute, painless, or postpartum thyroiditis  
Consumptive Hypothyroidism  
Rapid destruction of thyroid hormone due to D3 expression in large hemangiomas 
or hemangioendotheliomas  
Defects of Thyroxine to Triiodothyronine Conversion  
Selenocysteine insertion sequence–binding protein (SECIS-BP2) defect  
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Drug-Induced Thyroid Destruction  
Tyrosine kinase inhibitor (sunitinib)  
Central Hypothyroidism  
Acquired  
Pituitary origin (secondary)  
Hypothalamic disorders (tertiary)  
Bexarotene (retinaid X receptor agonist)  
Dopamine and/or severe illness  
Congenital  
TSH deficiency or structural abnormality  
TSH receptor defect  
Resistance to Thyroid Hormone  
Generalized  
“Pituitary” dominant 
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Signs and Symptoms of Hypothyroidism (Descending Order of Frequency)  
Symptoms 
    Tiredness, weakness 
    Dry skin 
    Feeling cold 
    Hair loss 
    Difficulty concentrating and poor memory 
    Constipation 
    Weight gain with poor appetite 
    Dyspnea 
    Hoarse voice 
    Menorrhagia (later oligomenorrhea or amenorrhea) 
    Paresthesia 
    Impaired hearing 
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Signs 
    Dry coarse skin; cool peripheral extremities 
    Puffy face, hands, and feet (myxedema) 
    Diffuse alopecia 
    Bradycardia 
    Peripheral edema 
    Delayed tendon reflex relaxation 
    Carpal tunnel syndrome 
    Serous cavity effusions 
 Cardiac involvement in myxedema was first described by Zondek in 
1918(12).The cardiovascular findings of hypothyroidism are more subtle. The 
clinical presentation of overt hypothyroidism is not obvious and most patients have 
few symptoms and signs (13).The CVS manifestations of hypothyroidism include 
the following: 
a) Reduced total intravascular volume 
b) Reduced contractility 
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c) Reduced heart rate (All leading to decreased cardiac output) 
d) Raised systemic vascular resistance (leading to increased diastolic blood 
pressure) 
e) Raised capillary permeability (leading to pericardial effusion) 
 Bradycardia and systemic hypertension, with narrow pulse pressure and 
slightly increased mean arterial pressure, and some degree of exercise impairment 
are the most-common findings in patients with overt hypothyroidism (13, 14). 
 No specific pathophysiological changes can be identified that characterize 
the myxedema heart. The cardiac silhouette is enlarged; however, heart weight is 
usually normal. Cardiac papillary muscle shows a depression of the force velocity 
curve and reduced rate of tension development, indicating significant contractile 
abnormalities. Myofibril swelling with loss of striation and some degree of 
interstitial fibrosis occurs on histological examination of hypothyroid hearts. In 
addition, accumulation of mucopolysaccharides can be demonstrated. 
INTERACTION OF THYROID HORMONES WITH THE SYMPATHETIC NERVOUS 
SYSTEM 
 Some clinical manifestations of hypothyroidism such as sinus bradycardia 
are suggestive of decreased sympathetic tone. But the catecholamine 
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concentrations are normal or decreased in hyperthyroidism and elevated in 
hypothyroidism.(15-17) The latter finding is not related to decreased norepinephrine 
clearance but rather to increased norepinephrine release from sympathetic 
nerves.(17).  This interpretation is strengthened by the observation that thyrotropin 
releasing hormone (TRH),which is elevated in primary hypothyroidism, directly 
stimulates sympathetic outflow within the central nervous system and may be 
taken up by nerve endings to serve as a neurotransmitter. This apparent paradox of 
clinical signs evoking decreased sympathetic tone in the presence of elevated 
norepinephrine release from sympathetic nerve endings is consistent with the 
hypothesis of desensitization to the effects of catecholamines in hypothyroidism. 
(18). 
HYPERTENSION 
 Three factors contribute to systemic hypertension in overt hypothyroidism. 
The first is the increase in peripheral vascular resistance (13) , the second is the 
increase in arterial stiffness, which likely results from myxedema of the arterial 
wall (19, 20) and the third is endothelial dysfunction. Systemic hypertension 
associated with overt hypothyroidism is poorly controlled by conventional 
treatments, whereas it promptly improves with achievement of euthyroidism (21). 
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Ikuo Saito et al in his study showed hypertension is more often associated with 
hypothyroidism than euthyroidism in patients over 50 years old, and that blood 
pressure is often reduced in response to adequate thyroid hormone replacement 
therapy alone (22) 
LV FUNCTION 
 The most-consistent cardiac abnormality recognized in patients with overt 
hypothyroidism is impairment of LV diastolic function, which is characterized by 
slowed myocardial relaxation and impaired early ventricular filling (20, 23). This is 
completely reversed by replacement therapy. 
 Bernadette Biondi et al in a study evaluated 26 patients (mean age, 36  yr) 
by Doppler-echocardiography, whereas a subgroup of 10 patients, randomly 
selected, were reevaluated after 6 months of L-T4 substitutive therapy. 
Echocardiogram examination showed no abnormalities of the left ventricular 
morphology and a slight, but not significant, reduction in the systolic function in 
the patient group. In contrast, Doppler derived indices of diastolic function showed 
significant prolongation of the isovolumic relaxation time, increased A wave and 
reduced early diastolic mitral flow velocity/late diastolic mitral flow velocity 
ratio.In the subgroup of 10 patients, thyroid hormone profile was normalized by 6 
months of L-T4 substitutive therapy, whereas no changes were observed in the left 
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ventricular morphology. Assessment of diastolic function showed significant 
shortening of isovolumic relaxation time, reduction of A wave, and increase of 
early diastolic mitral flow velocity/late diastolic mitral flow velocity ratio. These 
findings indicate that subclinical hypothyroidism affects diastolic function and that 
this abnormality may be reversed by L-T4 substitutive therapy. (24) 
 LV systolic function usually is only marginally subnormal, as demonstrated 
by slightly reduced values of ejection fraction and stroke volume (20, 21). Systolic 
function has been evaluated in overt and subclinical hypothyroidism by different 
techniques. All showed the abnormalities reverting on replacement therapy. 
PERICARDIAL EFFUSION 
 Pericardial effusions can occur consistent with observation that patients with 
hypothyroidism have an increase in volume of distribution of albumin and a 
decrease in lymphatic clearance function. Occasionally the pericardial effusions are 
quite large, causing the appearance of cardiomegaly on chest radiograph. Although 
rare, tamponade with hemodynamic compromise can occur. Echocardiography 
demonstrates small to moderate effusions in up to 30 percent of overtly 
hypothyroid patients, which resolve over a period of weeks to months after 
initiation of thyroid hormone replacement.(13) The fluid usually has a high 
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cholesterol and protein content and is sometimes  described as resembling 'gold 
paint’. 
 Kerber and Sherman (25) found echocardiographic evidence of pericardial 
effusion in 10 of 33 patients with hypothyroidism. Hardisty CA, Naik DR, Munro 
DS. studied 39 patients with untreated  hypothyroidism using echocardiography for 
the presence of a pericardial effusion. Effusions were present in twelve patients 
who tended to be more severely hypothyroid. 9 were reinvestigated during 
thyroxine replacement therapy and the effusions did not disappear until thyroid 
function tests had returned to normal. (26)  
LV MASS 
 Overt hypothyroidism may be associated with some increase in LV mass. In 
both hypothyroidism and myxedema, reversible diastolic abnormalities have been 
reported. In an echocardiographic study, asymmetric septal hypertrophy was found 
in 17 of 19 patients, and some of them had echocardiographic features similar to 
those found in hypertrophic obstructive cardiomyopathy. In 10 such patients, this 
abnormality resolved on return to euthyroid state. There is no good explanation for 
this finding that has been confirmed on postmortem examinations and may 
represent one potential cause of left ventricular diastolic dysfunction in 
hypothyroid patients. (27) 
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ANGINA 
 The increase in peripheral vascular resistance and arterial stiffness in overt 
hypothyroidism contributes to increased cardiac after load. This causes a 
disproportionate increase in myocardial oxygen uptake with respect to the level of 
cardiac performance explains in part why overt hypothyroidism may precipitate or 
worsen angina in patients with suspected or known ischemic heart disease (28) and 
why some of these patients have an improvement in anginal symptoms after 
thyroid hormone replacement is initiated. 
 Raised serum cholesterol level and other lipid abnormalities are known to 
occur in patients with hypothyroidism. Agdeppa er al.(29) found that high-density 
lipoprotein cholesterol (HDL-C) levels are reduced and low density lipoprotein 
cholesterol (LDL-C) levels are increased in hypothyroidism. The ratio between 
LDL-C and HDL-C is high in hypothyroid patients. According to Steinberg (30) 
ischemic heart disease is more prevalent among hypothyroid patients when 
hypertension is present.  
HEART FAILURE 
 Hypothyroidism may also rarely be the sole cause of heart failure. One such 
case has been reported.(31) A low heart rate, decreased myocardial contractility, and 
increased peripheral resistance can all lead to low cardiac output. Furthermore, left 
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ventricular filling may be impaired by the simultaneous presence of left ventricular 
hypertrophy, abnormal relaxation, and bradycardia. Heart failure may occur  
(32-34) when peripheral metabolic demand cannot be matched by an adequate cardiac 
output. In addition, cardiac tamponade may be a rare cause of cardiac failure in 
myxedematous patients.(35) Heart failure is, however, more common in patients 
with underlying coronary artery disease Heart failure may be the result of patchy 
myocardial necrosis or ongoing ischemia, which may worsen at the time of thyroid 
replacement therapy, due to increased myocardial oxygen demand in the face of 
decreased coronary reserve. 
ECG 
 ECG in hypothyroidism is characterized by sinus bradycardia, low voltage, 
right bundle branch block (RBBB), flat or inverted T wave and prolongation of the 
action potential duration and the QT interval. The latter in turn predisposes the 
patients to ventricular arrhythmias, and cases of patients with acquired torsades de 
pointes that have improved or completely resolved with thyroid hormone 
replacement have been reported (36)  
LIPID ABNORMALITIES 
 Both the synthesis and the degradation of lipid are depressed in 
hypothyroidism. Degradation, however, is reduced to a greater extent, with a net 
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effect of accumulation of LDL and triglycerides (37).HDL concentrations are 
reduced. Plasma free fatty acid levels are decreased, and the mobilization of free 
fatty acids in response to fasting, catecholamines, and growth hormone is impaired. 
All of these abnormalities are relieved by treatment. 
 Patrícia De Fátima et al performed, a cross-sectional study with 226 
participants [subclinical hypothyroidism (SH) = 133 participants, manifest 
hypothyroidism (MH) = 23 participants, and euthyroidism (EU) = 70 participants]. 
The mean levels of atherogenic lipid variables were greater in MH than in SH and 
were greater in SH than in EU, although the differences between SH and EU did 
not reach statistical significance. The SH subgroup with greater serum thyrotropin 
(TSH) levels and that with positive antithyroperoxidase antibodies (TPO-Ab) had 
greater levels of triglycerides and of the atherogenic index Apo B/Apo A. A 
positive correlation exists between serum TSH and total cholesterol (rs = 
0.167; P = 0.006), triglycerides (rs = 0.219; P < 0.001), and ApoB levels (rs = 
0.205; P < 0.001). (38) 
 Subclinical hypothyroidism does result in a small increase in LDL 
cholesterol and a decrease in high-density lipoprotein cholesterol, changes that 
enhance the risk for development of atherosclerosis and coronary artery disease. 
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Ganotakis ES at al studied the frequency and type of lipid disorders associated with 
subclinical hypothyroidism (SH) in older women .Fasting serum lipid profiles and 
thyroid function tests were measured in 333 apparently healthy women (mean age: 
71.8 +/- 7 years). Low-density lipoprotein cholesterol (LDL-C) concentrations 
were higher in the women with SH (p = 0.037). The mean values of total 
cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), TC/HDL-C ratio, 
lipoprotein (a) (Lp[a]), apolipoprotein A-I (apo AI) apolipoprotein B100 (apo B) 
and apo B/apo A ratio were higher and triglycerides (TG) were lower, compared 
with those with normal levels of thyrotropin. Restoration of euthyroid status 
(thyroxine: 50-100 microg/day) in 17 SH women significantly improved TC (p = 
0.017), LDL-C (p = 0.014), TC/HDL-C (p = 0.05), LDL-C/HDL-C (p = 0.03), apo 
B (p = 0.013), and Lp(a) (p = 0.0005) values. Thyroid hormone replacement 
therapy significantly improved serum lipids. In particular, the reduction in LDL-C 
and Lp(a) concentrations may be of clinical benefit(39) 
SUBCLINICAL HYPOTHYROIDISM 
 Subclinical hypothyroidism is defined by elevated serum TSH level in the 
presence of normal levels of free thyroid hormones. Up to two thirds of patients 
have serum TSH between 5–10 mU/L and thyroid autoantibodies (40,41). Almost 
half of these individuals may progress to overt thyroid failure (42,43).Striking 
evidence indicates that elevated TSH levels in SH patients do not reflect pituitary 
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compensation to maintain euthyroidism but mild tissue hypothyroidism sensu 
strictu. Subclinical hypothyroidism alters lipid metabolism, atherosclerosis, cardiac 
contractility, and systemic vascular resistance.  
 A large study of women in Rotterdam showed that atherosclerosis and 
myocardial infarction increased with odds ratios of 1.7 and 2.3 in subclinical 
hypothyroid women, respectively. Restoration of serum TSH to normal after 
thyroid hormone replacement improved lipid levels, lowered systemic vascular 
resistance, and improved cardiac contractility.[44] Patients with subclinical 
hypothyroidism have prolonged isovolumic relaxation times, whereas systolic 
contractile function does not change.  
 Subclinical hypothyroidism is associated with an atherogenic lipid profile, 
characterized by increased circulating levels of total and low-density cholesterol 
and increased levels of oxidized low-density lipoproteins (45,46). Flow-mediated 
vasodilatation, a marker of endothelial function, is significantly impaired in 
subclinical hypothyroidism (47) 
  In general, resting heart rate and blood pressure are normal in subclinical 
hypothyroidism subjects (48-51). An increased prevalence of systemic hypertension 
have been reported in patients with subclinical hypothyroidism (52,53). The most-
consistent cardiac abnormality recognized in SH patients is LV diastolic 
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dysfunction, characterized by slowed myocardial relaxation and impaired early 
ventricular filling, both at rest and with exercise (48-51). In terms of systolic function, 
(48) documented improvement from pretreatment values, although no difference 
when compared with the control group. Among measures, parameters of LV 
morphology were shown to be significantly higher in patients with subclinical 
hypothyroidism compared with controls (52). In contrast, Biondi et al. (48) reported 
no abnormalities of LV morphology seen in the patient group. 
 TREATMENT 
 Levothyroxine sodium is the treatment of choice for the routine management 
of hypothyroidism. Adults with hypothyroidism require approximately 1.7 
microg/kg of body weight per day for full replacement. Children may require 
higher doses (up to 4 microg/kg of body weight per day). Older patients may need 
less than 1 microg/kg per day. Therapy is usually initiated in patients under the age 
of 50 years with full replacement. For those patients who are older than 50 years, 
or in younger patients with a history of cardiac disease, a lower initial dosage  is 
indicated, starting with 0.025 to 0.05 mg of levothyroxine daily, with clinical and 
biochemical reevaluations at 6- to 8-week intervals until the serum TSH 
concentration is normalized. Certain drugs, eg, cholestyramine, ferrous sulfate, 
sucralfate, and aluminum hydroxide antacids, may interfere with levothyroxine 
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absorption from the gut. The response to treatment of hypothyroidism is 
predictable, especially from a cardiovascular perspective (53) 
Subclinical Hypothyroidism 
 The treatment of subclinical hypothyroidism remains controversial. It is 
accepted by some that treatment is indicated in patients with TSH levels >10 
µIU/mL or in patients with TSH levels between 5 and 10 µIU/mL in conjunction 
with goiter or positive anti-thyroid peroxidase antibodies (or both). These patients 
have the highest rates of progression to overt hypothyroidism. An initial dosage of 
levothyroxine of 25 to 50µg/day can be used, the serum TSH level should be 
measured in 6 to 8 weeks, and the levothyroxine dose should be adjusted as 
necessary. The target TSH level should be between 0.3 and 3.0 µIU/mL. It may 
improve memory related abilities, depressive features; lipid abnormalities like 
hypercholesterolemia may also improve. Currently the treatment is recommended 
only if associated with goiter, anti thyroid antibodies, dyslipidemia, infertilities, 
menstrual irregularities. 
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MATERIALS AND METHODS 
 The study was conducted in the Out Patient Department, Department of 
Endocrinology, Institute of Internal Medicine, Madras Medical College & Rajiv 
Gandhi Government General Hospital, Chennai. 
Ethical committee Approval- Obtained 
Design of study- Descriptive Study 
Sample size - In the study period patients attending the Endocrinology OPD, 
Institute of Internal Medicine after applying inclusion and exclusion criteria, 80 
patients were included in the study. Patients thus selected were divided into three 
categories according to the level of thyroid stimulating hormone (TSH) as follows: 
(i) Mild hypothyroidism (< 20 mIU/ml) 
(ii) Moderate hypothyroidism (20 – 50 mIU/ml) 
(iii) Severe hypothyroidism (> 50 mIU/ml) 
SUBJECTS 
Inclusion criterita 
1. Female patients older than 18yrs of age  
2. Patients with subclinical hypothyroidism (defined as TSH > 5.5µIU/ml with 
normal free T4 and free T3) 
3. Patients with overt  hypothyroidism  
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Exclusion criteria 
1. Patients already on treatment with Thyroxine. 
2. Patients less than 18 years of age 
3. Patients with known primary cardiac disease, DM,Hypertension. 
4. Patients who were taking drugs that alter the cardiovascular functions like 
amiadarone, Beta blockers and calcium channels blockers etc. 
 Patients attending the Endocrinology outpatient who satisfied the inclusion 
criteria were registered for the study after obtaining their consent. A detail 
questionnaire was used to elicit symptoms of hypothyroidism. The patient was 
examined to look for signs of hypothyroidism. Special attention was given to 
examination of the cardiovascular system. 
All the patients were evaluated for following parameters: 
a. Pulse rate 
b. Blood pressure - measured thrice and the average was taken (As per 
recommendations of Joint National Committee – 7) 
c. Body mass index (< 25 is normal) 
d. Serum total T4 (Normal Range – 5.4–11.7 ug/dL)(54) 
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e. Serum TSH. (Normal Range – 0.34–4.25 mIU/L)(54) Measurement of 
total T3 and T4 were done by radioimmunoassay (RIA) technique and 
TSH levels were measured by Immuno-radiometric assay (IRMA). 
f. Chest x ray-For cardiomegaly 
g. ECG 
h. Total cholesterol (As per recommendations of American National 
Cholesterol Eradication Programe III) 
i. USG neck 
j. FNAC thyroid 
Echocardiography was done in all the patients and the following parameters were 
looked for 
1. Chamber dimensions:  
 In M Mode transthoracic echocardiogram the LV internal diameter 
(diastolic), posterior wall thickness and the interventricular septal wall thickness 
were measured. Reference values for LV linear dimensions as per the  ASE 
COMMITTEE RECOMMENDATIONS ,2005(54). Asymmetric hypertrophy is 
defined as a ratio of interventricular septal thickness and left ventricular 
posterior wall thickness greater than 1.3. 
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 Women Men 
 
Reference 
range 
 
Mildly 
abnormal 
 
Moderately
abnormal 
 
Severely 
abnormal
 
Reference
Range 
Mildly 
abnormal 
 
Moderately
abnormal 
 
Severely 
abnormal 
Septal 
thickness, 
cm  
0.6-0.9 1.0-1.2 1.3-1.5 >1.6 0.6-1 1.1-1.3 1.4-1.6 >1.7 
Posterior 
wall 
thickness, 
cm 
0.6-0.9 1.0-1.2 1.3-1.5 >1.6 0.6-1 1.1-1.3 1.4-1.6 >1.7 
LV 
diastolic 
diameter 
3.9–5.3 5.4–5.7 5.8–6.1 ≥6.2 4.2–5.9 6.0–6.3 6.4–6.8 ≥6.9 
 
2. Diastolic function:  
 The E/A ratio is the ratio between early (E) and late (atrial - A) ventricular 
filling velocity (mitral inflow velocity).The early (E) diastolic one is caused by 
accumulation of blood in the atria during previous systole, and second, a late one 
created by atrial contraction (A).  
Grading of ventricular diastolic dysfunction 
 Grade I - abnormal relaxation pattern or diastolic dysfunction with reversal 
of the normal E/A ratio. This pattern may develop normally with age in some 
patients and many grade I patients will not have any clinical signs or symptoms of 
heart failure. 
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Grade II-Pseudo normal filling dynamics. This is considered moderate 
diastolic dysfunction and is associated with elevated left atrial filling pressures. 
These patients more commonly have symptoms of heart failure and many have left 
atrial enlargement due to the elevated pressures in the left heart. 
 Grade III-Reversible restrictive diastolic dysfunction. There is reversal of 
their diastolic abnormalities on echocardiogram when they perform the Valsalva 
maneuver  
 Grade IV – Fixed restrictive diastolic dysfunction. No reversibility of their 
echocardiogram abnormalities.  
 Grade III and IV are both severe forms of diastolic dysfunction and patients 
tend to have advanced heart failure symptoms. 
3. Systolic function: 
  Echocardiography can measure several parameters as an expression of 
systolic function of the heart. These parameters are LVEF, fractional shortening, 
stroke volume and cardiac index, systolic tissue velocity of the mitral annulus and 
myocardium, strain, and regional wall motion analysis. The Parameters denoting 
Systolic function (55) are 
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Linear 
method  
Women Men 
Refer
ence 
range 
 
Mildly 
abnormal 
 
Moderately 
abnormal 
 
Severely 
abnormal 
 
Referen
ce 
Range 
Mildly 
abnormal 
 
Modera 
tely 
abnormal 
 
Severely 
abnormal 
Reference 
range 
 
Endocardial 
fractional 
shortening, % 
27–45 22–26 17–21 ≤16 25–43 20–24 15–19 ≤14 
Endocardial 
fractional 
shortening, 
% 
Midwall 
fractional 
shortening, % 
15–23 13–14 11–12 ≤10 14–22 12–13 10–11 ≤10 
Midwall 
fractional 
shortening, 
% 
2D Method 
Ejection 
fraction, % 
≥55 45–54 30–44 <30 ≥55 45–54 30–44 <30 
2D Method 
Ejection 
fraction, % 
 
 
LV Ejection Fraction =   EDV-ESV 
                                     -------------------   X 100 
                                              EDV 
Grading of systolic dysfunction: 
i) Mild - EF 45 to 55 % 
ii) Moderate - EF 35 to 45% 
iii) Severe - EF < 35% 
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Fractional Shortening = LVID (D) – LVID(S) 
                                  ---------------------------------- X 100 
                                                 LVID (D) 
 This systolic function parameter is now rarely used for diagnosis or clinical 
decision making 
4. Wall Motion abnormalities: 
 For purposes of regional wall motion analysis, the ASE has recommended a 
16-segment model or, optionally, a 17-segment model with an addition of the 
apical cap. The following numerical score is assigned to each wall segment on the 
basis of its contractile function as assessed visually: 1 = normal (>40% thickening 
with systole); 2 = hypokinesis (10% to 40% thickening); 3 = severe hypokinesis to 
akinesis (<10% thickening); 4 = dyskinesis; and 5 = aneurysm. On the basis of this 
wall motion analysis scheme, a wall motion score index (WMSI) is calculated to 
semiquantitate the extent of regional wall motion abnormalities 
5. Pericardial Effusion: 
The pericardial effusion is quantified by the amount of echo free space surrounding 
the heart. The pericardial effusion can be graded as: Minimal pericardial effusion: 
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Posterior atrio-ventricular groove shows echo free space, this is seen in systolic 
phase only. It represents normal pericardial fluid.  
Mild pericardial effusion: Echo free space < 1cm.  
Moderate pericardial effusion: Echo free space 1 – 2 cm. 
Large pericardial effusion: Echo free space > 2cm 
Statistical analysis 
SPSS12 and Excel were used for data analysis. 
Consent 
All participants gave written informed consent. 
 
Ethical Committee Approval 
Institutional  Ethical Committee approved the study 
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TABLE: 3    METABOLIC PARAMETERS IN HYPOTHYROIDISM 
 
3A. BMI (BODY MASS INDEX) 
 
 The mean BMI in the patients with subclinical hypothyroid was 27.06, while 
among the mildly hypothyroid it was 25.75. the moderately hypothyroid patients 
had a mean BMI of 26.23 and the severely hypothyroid was 30.16.The two-tailed P 
value by the one sample t test is 0.0001, considered extremely significant. 
 
 
 
 
BMI 
 
 
    Subclinical 
Hypothyroidism 
(n=30) 
 
Hypothyroidism 
(p=0.0019) 
 
 
 
 
Total 
(n=80)  
Mild 
(n=12) 
Moderate
(n=13) 
Severe 
(n=25) 
Normal   
<25 12 6 6 1 
 
25 
(31.25%) 
Overweight 
25 to 30 10 4 4 10 
 
28 
(35%) 
Obese  
  >30 8 2 3 14 
 
27 
(33.75%) 
Mean 27.06 25.75 26.23 30.16 
 
P value = 
0.0001 
SD 2.9 3.64 3.78 2.95 
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3B. WAIST CICUMFERENCE 
 
 
Waist (cm) 
Subclinical 
Hypothyroidism Hypothyroidism 
Mild Moderate Severe 
Female P=  0.0972 
<88 19(63.33%) 8(66.67%) 7(53.84%) 8(32%)
>88 11(36.67%) 4(33.33%) 6(46.15%) 17(68%)
Mean 83.06 84.91 87.46 89.48 
SD 13.44 5.91 6.47 6.00 
 
 Among the study population 11 females (36.66%) of the subclinical 
hypothyroid patients were found to have increased waistline, while 4 females 
(33.33%) of the mild hypothyroid group had increased waistline. 6 females 
(46.15%) of the moderately hypothyroid patients and 17 females (68%) were found 
to have increased waistline.  Comparing the means by the  One-way Analysis of 
Variance (ANOVA) p value was 0.0858 not statistically significant. 
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TABLE:5 MYOCARDIAL WALL THICKNESSES (MM) IN 
HYPOTHYROID PATIENTS. 
5A. LVPW THICKNESS 
 
Types Reference 
range 
(6-9 mm) 
Abnormal 
(>9 mm) 
 
P value 
 
 
Hypothyroidism 
 
Mild 11 1  
0.001327 Moderate 7 6 
Severe 7 18 
Total 25 25 
Subclinical Hypothyroidism 
 
28 
 
 
2 
 
< 0.0001 
 
 Among the mildly hypothyroid patients abnormal LVPW thickness was 
found in 1 (8.3%) and in the moderately hypothyroid it was noted in 6 (46.15%).18 
(72%) out of the severely hypothyroid patients had increased LVPW thickness, 
while this finding was noted in only 2(6.66%) of the subclinical hypothyroid 
patients. On comparing the occurrence of increased LVPW thickness with 
increasing severity of disease by the Chi-squared Test for Independence  the P 
value is 0.0013 and on  comparing the hypothyroid with the subclinical 
hypothyroid patients by the Fisher's Exact Test the two-sided P value is < 0.0001 
with Relative risk = 7.132.  
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5B.IVS THICKNESS 
 
Types Reference 
range 
(6-9 mm) 
Abnormal 
(>9 mm) 
 
P value 
Hypothyroidism 
 
Mild 11 1   
0.0007 Moderate 4 9 
Severe 7 18 
Total 22 28 
Subclinical Hypothyroidism 
 25 5 
0.0009 
 
 Among the mildly hypothyroid patients abnormal septal wall thickness was 
found in 1 (8.3%) and in the moderately hypothyroid it was noted in 9 (69.23%).18 
(72%) out of the severely hypothyroid patients had increased septal wall thickness, 
while this finding was noted in only 5(16.66%) of the subclinical hypothyroid 
patients. On comparing the occurrence of increased septal wall thickness with 
increasing severity of disease by the Chi-squared Test for Independence  the P 
value is 0.0007and on  comparing the hypothyroid with the subclinical hypothyroid 
patients by the Fisher's Exact Test the two-sided P value is 0.0009 with Relative 
risk = 0.5280. 
 
. 
48 
 
 
 
 
 
 
 
 
 
0
2
4
6
8
10
12
14
0 50 100 150 200
IV
 S
ep
ta
l w
al
l t
hi
ck
ne
ss
TSH
Fig 5: IV Septal wall thickness
Echo‐septal wall 
thickness (mm)
Linear (Echo‐septal 
wall thickness (mm))
0
2
4
6
8
10
12
14
0 50 100 150 200LV
 P
os
te
ri
or
 w
al
l t
hi
ck
ne
ss
 (m
m
)
TSH
Fig 6:LV Posterior wall thickness
Echo‐septal wall 
thickness (mm)
Linear (Echo‐septal 
wall thickness (mm))
49 
 
TABLE: 6 CARDIAC CHAMBER SIZE (CM) IN HYPOTHYROID   PATIENTS 
 
 
LVID(D) cm 
(p=0.6250) 
 
Subclinical 
Hypothyroidism 
Hypothyroidism 
Mild Moderate Severe 
<5.4 12 13 24 30 
>5.3 0 0 1 0 
 
 The Cardiac chamber size was found to be normal in the study population 
.On statistical analysis with Fisher exact probabilities test the p value was 0.6250, 
statistically insignificant showing that the cardiac chamber size is not affected by 
hypothyroidism . 
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TABLE :7 LV SYSTOLIC FUNCTIONS IN HYPOTHYROID PATIENTS
 
 
 
Parameters 
 
 
Types EF ( % ) 
 
 
FS (%) 
RWMA 
 
 
Global 
Hypokinesia
>55% <55% 
 
>30%
 
<30%
Subclinical 
Hypothyroidism 
  
30 
 
0 
 
30 
 
0 
0 0 
Hypothyroidism  
Mild 12 0 12 0 0 
 
0 
Moderate 12 1 13 
 
0 
 
0 
 
0 
Severe 23 2 25 
 
0 
 
0 
 
0 
P value 
 0.2911 1 
- - 
 
 On statistical analysis of the ejection fraction and fractional shortening with 
the severity of the disease, the p values were >0.05 and not significantly 
associated. Thus the LV systolic functions as measured by ejection fraction and 
fractional shortening were not associated with the severity of hypothyroidism. No 
wall motion abnormalities or global hypokinesia was detected. Only 2 (8%) of the 
severely hypothyroid group and 1(7.69%) in the moderately hypothyroid group had 
reduction of ejection fraction. 
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TABLE 8: DIASTOLIC DYSFUNCTION IN HYPOTHYROIDISM 
 
 
Diastolic dysfunction was found in 1(8.33%) patient in the mild hypothyroid 
group and in 2 (15.38%) of the moderately hypothyroid group.9 (36%) patients of 
the severely hypothyroid group had diastolic dysfunction. In the subclinical 
hypothyroid group the same was noted in 3(10%) patients. 
 
 
 
 
 
 
Types 
 E/A Ratio 
 
P value 
>1 
 
<1 
Hypothyroidism Mild 
11 
 
1 
 
 
 
0.1714 
Moderate 
11 
 
2 
Severe 
16 
 
9 
Total 
38 
 
12 
Subclinical Hypothyroidism 
27 
 
3 
     0.1481 
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TABLE: 9 ANALYSES OF THE MEANS OF ECHO 
PARAMETERS 
Mean 
values 
Subclinical 
Hypothyroidism
Hypothyroidism  
P value 
Mild Moderate Severe 
LVPW(mm) 8.49 8.74 9.23 10.54 < 0.0001 
IVSW(mm) 8.74 8.75 9.20 10.42 < 0.0001 
LVID(D)cm 4.44 4.51 4.41 4.58 0.4542 
EF % 62 63.08 61.61 61.6 0.8967 
FS % 33.86 34.08 34.16 34.44 0.8260 
E/A 1.50 1.69 1.62 1.25 0.0098 
 
On statistical analysis by one way analysis of variance (ANOVA) it was 
found that LVPW (mm) ,IVSW(mm) and E/A were significantly associated with 
the severity of hypothyroidism, while EF %, FS %and LVID (D)cm were 
significantly not associated. 
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TABLE 10: PERICARDIAL INVOLVEMENT IN  
HYPOTHYROID PATIENTS 
 
Pathology Subclinical 
Hypothyroidism
Hypothyroidism 
Mild Moderate Severe 
Mild PE 1 1 2 2 
Mod PE 0 0 1 6 
Large PE 0 0 1 2 
Pericardial 
thickening 0 0 0 0 
Constrictive 
physiology 0 0 0 0 
Total 1 1 4 10 
 
Pericardial effusion was observed in 1(8.33%) of the mild hypothyroid 
patients, and also in 4 (30.76%) patients of the moderately hypothyroid group. 10 
(40%) of the severely hypothyroid had the same .No pericardial thickening or 
Constrictive physiology was made out. 
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TABLE 11: AGE AND CHAMBER THICKNESS 
 
 
Age   
 
MEAN LVPW 
(MM) 
 
MEAN IVSW 
(MM) 
20-29 9.21+/- 1.1 9.15+/-0.88 
30-39 9.56+/-1.29 9.69+/-1.2 
40-49 8.4 +/- 0.63 8.4+/- 0.63 
50-59 9.81+/-1.59 9.54+/- 1.3 
P VALUE  < 0.0001 < 0.0001 
 
There was a trend of increasing wall thickness with age in the patients. 
 
 
7.5
8
8.5
9
9.5
10
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Fig 7:Age and chamber thickness
LVPW
IVSW
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TABLE 12: MULTIPLE REGRESSION ANALYSIS WITH DEPENDENT VARIABLE IV 
SEPTAL WALL THICKNESS AND INCLUDING AGE AND SEVERITY OF 
HYPOTHYROIDISM 
 
VARIABLE   COEFFICIENT SE 95% 
CONFIDENCE 
INTERVAL 
T RATIO P VALUE
CONSTANT 3.695        0.7572     2.170   TO  5.221 19.220       < 0.0001 
AGE -0.002064    0.008946  -0.02009  TO 
0.01596 
0.5324   0.8186 
TSH 0.008883     0.002195  0.004461    TO 
0.01331 
9.970 0.0002 
 
R squared    0.8387 
Adjusted R squared      0.8281 
A multiple regression analysis was done with the dependent variable as IV 
septal wall thickness and entering the significant items, including age and TSH  as 
variable, it was found that only TSH continued to be significant.  
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TABLE 13: MULTIPLE REGRESSION ANALYSIS WITH DEPENDENT 
VARIABLE LVPW THICKNESS AND INCLUDING AGE AND 
SEVERITY OF HYPOTHYROIDISM 
 
 
VARIABLE COEFFICIENT SE 95% CONFIDENCE 
INTERVAL 
T RATIO P VALUE 
CONSTANT 7.995 0.5247 6.938   TO  9.051 15.236 < 0.0001 
AGE 0.01518 0.01494 - 0.01491 TO  0.04527 1.016 0.3149 
TSH 0.01919 0.002430 0.01430 TO  0.02408 7.898 < 0.0001 
 
R squared               0.5930 
Adjusted R squared      0.5756 
 A multiple regression analysis was done with the dependent variable as 
LVPW thickness and entering the significant items, including age and TSH as 
variable, it was found that only TSH continued to be significant. 
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DISCUSSION 
 
 The cardiac complications of long standing hypothyroidism are serious if are 
not diagnosed properly earlier. Echocardiography as a non-invasive method can 
play important role in recognizing the cardiac pathology as well as to follow up 
effect of the therapy.  
 In this study of Indian population, we evaluated the cardiovascular function 
in newly detected primary overt and subclinical hypothyroidism. 80 patients were 
included in our study of which 37% were in the age group of 21 to 30. Majority of 
the patients were in the age group of 31 to 40 years of age with 40% prevalence. 
13% patients were in the age group of 41 to 50.About 10% patients were in the age 
of 51 to 60.The mean age was   35.21 +/- 9.74 Yrs.  
 Among the 80 patients included in our study, subclinical hypothyroid 
patients were majority with 38% in number. Among the hypothyroid patients, 15% 
patients had mild hypothyroidism while 16% had moderate hypothyroidism. 
Severe hypothyroid constituted the rest with 31%. 
Metabolic parameters in Hypothyroidism 
 In our study we found that the mean BMI in the patients with subclinical 
hypothyroid was 27.06, while among the mildly hypothyroid it was 25.75. The 
moderately hypothyroid patients had a mean BMI of 26.23 and the severely 
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hypothyroid was 30.16. BMI was significantly associated with the severity of the 
disease. Among our study population 36.66% of the subclinical hypothyroid 
patients were found to have increased waistline, while 33.33% of the mild 
hypothyroid group had increased waistline. 46.15% of the moderately hypothyroid 
patients and 68% were found to have increased waistline. 
 This is similar to the observations by Brunilda Figueroa et al (56) who in their 
study found that the mean TSH level was 2.2  mU/L for women and 1.9 mU/L for 
men. Mean BMI was 32.8 kg/m 2 for women and 35.9 kg/m for men. Females had 
a mean fat percent of 38.1% and males had 31.4% in their study. 
 However Manji et al (57) found no association between serum TSH and free 
T3 concentrations within the normal range and BMI. In contrast, Knudsen et al (58) 
found that thyroid function could be one of several factors that act in concert to 
determine body weight. 
 Dyslipidemia is a common finding in patients with not only overt but 
subclinical hypothyroidism also, mainly concerning total and LDL cholesterol and 
less often HDL cholesterol, triglycerides, lipoprotein (a), apolipoprotein A1, and 
apolipoprotein B. Dyslipidemia coexists with various metabolic abnormalities and 
induce insulin resistance and oxidative stress via a vice-vicious cycle. The above 
associations in combination with the thyroid hormone induced hemodynamic 
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alterations, might explain the increased risk of coronary artery disease, cerebral 
ischemia risk, and angina pectoris in older patients.   
 In our study the Mean Total Cholesterol for mild hypothyroid patients is 
203.16 mg /dl while the mean for moderate hypothyroid patients is 220.76 mg/dl. 
The severely hypothyroid had a mean of 253.32 while the subclinical hypothyroid 
patients had a mean of 217.6mg/dl. The Mean Triglycerides for mild hypothyroid 
patients is 134.66 mg /dl while the mean for moderate hypothyroid patients is 133 
mg/dl. The severely hypothyroid had a mean of 165.32 while the subclinical 
hypothyroid patients had a mean of 154 mg/dl. Both these lipid parameters were 
found to be statistically significantly associated with the severity of 
hypothyroidism. 
   Similar findings, that hypothyroidism is associated with an atherogenic 
 lipid profile was shown by O'Brien T et al (59) in a study of 268 patients 
with primary hypothyroidism and 27 with secondary hypothyroidism, who were 
examined in the Thyroid Clinic at the Mayo Clinic during a 1-year period. They 
were reviewed found significant associations of  total thyroxine with total 
cholesterol and triglycerides and thyroid-stimulating hormone with total 
cholesterol and low-density lipoprotein cholesterol. 
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ECG Changes 
 In our study low voltage complex was the commonest ECG finding with 25 
% prevalence. Sinus bradycardia was found in 22.5%. Bundle branch blocks and 
rhythm changes in the form of atrial fibrillation was found in 3.75% and 5 % 
respectively. This was in accordance with the known ECG changes which are 
expected to occur in hypothyroidism. Prolongation of the QT interval, decreased P-
wave voltage, prolonged AV conduction time, intraventricular conduction 
disturbances, and nonspecific ST-T-wave abnormalities were not observed in our 
study population. 
Myocardial wall thickness in hypothyroidism 
 Alvani D. Santos et al (60) first reported in 1979 a reversible cardiomyopathy, 
manifested by asymmetric septal hypertrophy in untreated hypothyroid patients. 
Among the mildly hypothyroid patients abnormal LVPW thickness was found in 1 
patient and in the moderately hypothyroid it was noted in 6 patients .18 out of the 
severely hypothyroid patients had increased LVPW thickness, while this finding 
was noted in only 2 of the subclinical hypothyroid patients. Significant association 
was found between the occurrence of increased LVPW thickness and the severity 
of disease.  
62 
 
 1 among the mildly hypothyroid patients had abnormal septal wall thickness 
and in the moderately hypothyroid it was noted in 9 patients.18 of the severely 
hypothyroid patients had increased septal wall thickness, while this finding was 
noted in only 5 of the subclinical hypothyroid patients. On comparing the 
occurrence of increased septal wall thickness with increasing severity of disease it 
was found to be statistically significant. 
 Rawat and Satyal (61) in their study showed relatively increased thickness of 
IVS and LVPW (1.2/1.7 and 1.1/1.6 cm) when compared to the treated patients 
(0.9/1.4 and 0.9/1.3 cm) or control subjects (0.8/1.3 and 0.7/1.2 cm). But on age 
group analysis it was found that this difference was more marked in older patients. 
In our study however we found that although there was a trend of increasing wall 
thickness with age these changes on multiple regression analysis with the 
dependent variable as IVseptal wall thickness and LVPW thickness including age 
and TSH as variable, it was found that only TSH continued to be significant. 
Jagdish et al (62) in their study showed that IVS and LVPW thickness decreased 
after treatment from 11.77 ± 1.73 to 11.33 ± 109 and 11.97 ± 1.83 to 11.40 ± 1.06 
respectively . 
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Cardiac chamber size in hypothyroidism 
The Cardiac chamber size was found to have a statistically insignificant 
association with hypothyroidism. This shows that the cardiac chamber size is not 
affected by hypothyroidism. Similar observations were also made by Varma R et al 
(63). 
LV functions 
 The LV systolic functions as measured by ejection fraction and fractional 
shortening were not statistically associated with the severity of hypothyroidism. No 
wall motion abnormalities or global hypokinesia was detected. Only 2 (8%) of the 
severely hypothyroid group and 1(7.69%) in the moderately hypothyroid group had 
reduction of ejection fraction  
 In the study by Jagdish et al (62), although FS increased from 26.43 ± 2.79 to 
26.73 ± 2.64 and EF showed increased from 53.93 ± 5.50 to 54.83 ± 4.64 , it was 
statistically not significant. Rawat et al (61) showed no significant change in 
parameters of systolic function while Monzani et al (64) found that FS and thus 
systolic function of LV significantly improved after treatment. 
  In our study diastolic dysfunction was found in 1(8.33%) patient in 
the mild hypothyroid group and in 2 (15.38%) of the moderately hypothyroid 
group.9 (36%) patients of the severely hypothyroid group had diastolic 
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dysfunction.. Similar findings of diastolic dysfunction were made by Almira 
Hadžovic-Džuvo et al (65), and Rajan et al (66). Biondi B,et al (67) in their study of 
subclinical hypothyroid patients showed significant prolongation of the isovolumic 
relaxation time (94 +/- 13 vs. 84 +/- 8 msec; P < 0.001), increased A wave (55 +/- 
13 vs. 48 +/- 9 cm/sec; P < 0.05), and reduced early diastolic mitral flow 
velocity/late diastolic mitral flow velocity ratio (1.4 +/- 0.3 vs. 1.7 +/- 0.3; P < 
0.001) indicating an early diastolic dysfunction. In our study diastolic dysfunction 
was noted in 3(10%) patients of the subclinical hypothyroid group which was 
insignificant. 
Pericardial pathology in Hypothyroidism 
 Pericardial effusion may occur in 30 % to 80% of patients with 
hypothyroidism. Pericardial effusion was observed in 1(8.33%) of the mild 
hypothyroid patients, and also in 4 (30.76%) patients of the moderately 
hypothyroid group. 10 (40%) of the severely hypothyroid had the same .No 
pericardial thickening or Constrictive physiology was made out. There was a 
striking correlation between severity of disease and pericardial effusion. 
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LIMITATIONS OF STUDY 
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LIMITATIONS 
 
 
1. The study was done on a sample of patients in the outpatient department. This 
makes the results of the study less generalizable to the overall population of 
hypothyroid patients. 
2. The sample size of 80 was relatively small to detect fine associations 
especially in the presence of multiple confounding variables. 
3. The cross sectional nature of the study makes it possible that the conclusions 
made may be unstable, or that they may be reflective of a phenomenon 
particular to one phase of illness. 
4. The follow-up of the patients after replacement of thyroxine was not done due 
to several reasons. If done it could have highlighted more on the reversibility 
of the cardiovascular changes. 
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CONCLUSION 
1. Increased interventricular septal and left ventricular posterior wall 
thicknesses with diastolic dysfunction are some of the earliest cardiac 
features of progressive thyroid failure. 
2. The magnitude of the lipid changes and the subtle impairment of left 
ventricular diastolic function in subclinical hypothyroidism patients as 
shown in our study may justify use of hormone replacement even without 
overt cardiac symptoms. 
3. An early diagnostic approach in patients with hypothyroidism will surely 
diminish the extent of cardiac complication which accompanies it. 
4. Echocardiography is a useful noninvasive tool in assessing the response to 
replacement therapy. 
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                                                               PROFORMA 
 
Name:                                                                            Age:                       Sex: 
Address:                                                                        Presentation: First/ Refferal                        
Occupation: 
Op\IP No:                                                      Contact no: 
SYMPTOMS: Duration 
Asymptomatic                                               Fatigue /Irritability                                       
Neck swelling                                                Depression / Anxiety                                    
Skin changes                                                 Weight gain /loss 
Cold /Heat intolerance                                  Sleepiness/ Insomnia                                    
Hair loss                                                        Myalgia/arthralgia                                                    
Muscle cramps /weakness                            Hard of hearing /Hoarseness of voice                       
Constipation /Loose stools/other bowel symptoms 
Breathlessness /Chestpain/ Palpitation /Syncope 
PAST HISTORY: 
CAD                                  Dyslipidemia                          DM                                   
Hypertension                     TB                                          Thyroidectomy                        
Any other relevant past history 
PERSONAL HISTORY: 
Alcohol                            Drug abuse                              Smoking                                               
MARITAL STATUS: Married/unmarried 
MENSTRUAL HISTORY: Amenorrhea / oligomenorrhea /Menorrhagia /Menopause 
OBSTETRIC HISTORY: Secondary /primary Infertility 
TREATMENT HISTORY: H/oDrugs (Thyroxin / Lithium /Amiadarone /antithyroid 
/Interferon), Radio iodine, H/o neck Radiation. 
SALT INTAKE: Iodised / non iodised 
 
GENERAL EXAMINATION: 
Built                                                   Nourishment  
Height:                                              Weight:                                          BMI  
Pallor            Icterus              Cyanosis                Clubbing                   
Lymphadenopathy                  Edema                                              
Pulse rate:                                     BP:                                    RR:                       
Temp: 
Peripheral pulses 
Facies -Anxious/dull/ normal 
Eyes-Periorbital Puffiness /protruding/normal 
Skin -Dry Coarse/wet 
Loss of Hair 
THYROID: 
Diffuse/Nodular/Thyroidectomy scar 
CVS 
RESPIRATORY SYSTEM 
ALIMENTARY SYSTEM 
MUSCULO SKELETAL 
NERVOUS SYSTEM 
INVESTIGATIONS 
TFT- T3 T4, fT4 TSH 
FLP- T. CHOLESTEROL, LDL, HDL, TG 
Hb                                                   ESR                               Blood sugar 
ECG       
 
 
                                                                       
ECHOCARDIOGRAPHY   
Septal wall thickness                                     LV Posterior wall thickness                            
Fractional shortening                                     Ejection fraction                                      
Diastolic dysfunction (E/A ratio)                  LVID 
Pericardial effusion                                       RWMA 
Hypokinesia 
